Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. (Nasdaq: AZTA) is a life sciences company focused on cold-chain sample management and multiomics services. News about AZTA often centers on how its sample management solutions, biorepository network and genomic services support drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions.
On this page, readers can follow company announcements related to financial results, segment performance in Sample Management Solutions and Multiomics, and updates on margin trends and cost structure. Earnings releases and accompanying commentary provide insight into revenue contributions from products and services, as well as the company’s efforts to streamline operations and refine its portfolio.
Azenta’s news flow also includes strategic transactions and capital allocation decisions, such as the definitive agreement to sell its B Medical Systems business and the authorization of a share repurchase program. These items illustrate how the company prioritizes core capabilities and balances investment in growth with returning capital to shareholders.
Another key theme in AZTA news is partnerships and collaborations. Recent releases describe Azenta’s role in supporting the PRECEDE Foundation’s pancreatic cancer early detection efforts through secure sample storage, and its collaboration with Frenova and Nephronomics, where GENEWIZ by Azenta provides genomic sequencing and Azenta manages long-term sample storage for a large kidney disease research program.
Investors and researchers can use this news feed to monitor developments in Azenta’s sample management and multiomics businesses, track major collaborations and stay aware of governance and shareholder-related events such as investor days, conference participation and annual meeting information.
Azenta, Inc. (Nasdaq: AZTA) reported Q1 fiscal 2022 results with revenue of $140 million, an 18% increase year-over-year. Life Sciences Services grew 24%, while Life Sciences Products saw a 10% rise. Diluted EPS from continuing operations was $0.04, with total diluted EPS at $0.58. The company completed the divestiture of its semiconductor automation business for $3 billion, expected to net about $2.4 billion. Guidance for Q2 2022 anticipates revenue between $137 million and $147 million, with non-GAAP earnings per share between $0.07 and $0.15.
Azenta, Inc. (Nasdaq: AZTA) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, presenting at 10:30 a.m. EST. The company, a leader in life sciences solutions, recently rebranded from Brooks Automation, enhancing their focus on critical areas like drug development and clinical research.
Headquartered in Chelmsford, MA, Azenta aims to expedite breakthroughs in healthcare through reliable cold-chain sample management and genomic services. For details, visit www.azenta.com.
Azenta, Inc. (Nasdaq: AZTA) announced the successful completion of the sale of its Semiconductor Solutions Group to Thomas H. Lee Partners for $3.0 billion in cash, with net proceeds expected to be about $2.4 billion. The company allocated approximately $50 million of the sale proceeds to pay off its term loan, while terminating its revolving line of credit. Following this transaction, Azenta will concentrate exclusively on the life sciences industry, planning to utilize the net proceeds for strategic investments.
Azenta, Inc. (Nasdaq: AZTA) will announce its fiscal 2022 Q1 earnings on February 8, 2022, after market close. A conference call to discuss the results will be held the same day at 4:30 p.m. ET. Investors can access the live webcast on Azenta's website, with a replay available on February 9 at 8:30 a.m. ET. The company, a leader in life sciences solutions, has rebranded from Brooks Automation, Inc. and is in the process of selling its Semiconductor Solutions Group business, which is classified as discontinued operations for reporting purposes.
Azenta, Inc. (Nasdaq: AZTA) appointed Matthew McManus as Chief Operating Officer, effective January 17, 2022. Dr. McManus, with over 25 years in the life sciences sector, will oversee Life Sciences Products, Services, and commercial operations, reporting directly to the CEO. He previously held senior roles at Bio-Techne and Asuragen. The company has transitioned its name and ticker from Brooks Automation, Inc. to Azenta as of December 1.
Azenta specializes in life sciences solutions, including cold-chain sample management and genomic services.
Azenta, Inc. (Nasdaq: AZTA) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 p.m. EST. The conference will be held virtually, and the presentation can be accessed through the Azenta investor relations website. A replay will be available post-event. Recently rebranded from Brooks Automation, Azenta provides life sciences solutions and cold-chain sample management services globally. The company is headquartered in Chelmsford, MA, and operates in North America, Europe, and Asia.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 24th Annual Needham Virtual Growth Conference on January 10, 2022, with a webcast starting at 1:15 p.m. EST. The event will be accessible via the Azenta investor relations website, with a replay available afterward.
Previously known as Brooks Automation, Inc., Azenta focuses on life sciences, offering cold-chain sample management and genomic services. The company also reports the Semiconductor Solutions Group as discontinued operations due to a pending sale.